Catalog No.
VHJ46901
Species reactivity
Human
Host species
Human
Isotype
IgG1,Kappa
Clonality
Monoclonal
Target
Cell surface A33 antigen, GPA33, Glycoprotein A33
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q99795
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0095
GPA33 expression in colorectal cancer can be induced by WNT inhibition and targeted by cellular therapy., PMID:39472498
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten., PMID:39168519
Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses., PMID:33052220
A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis., PMID:31928310
An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy., PMID:31891487
Dual Radionuclide Theranostic Pretargeting., PMID:31483993
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers., PMID:30082472
A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer., PMID:29935333
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates., PMID:26596724
Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts., PMID:25883890
68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers., PMID:24589653
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET., PMID:22068895
Studies of intestinal morphology and cathepsin B expression in a transgenic mouse aiming at intestine-specific expression of Cath B-EGFP., PMID:21871011
A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models., PMID:19336523
Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer., PMID:18360720
TGF-betaRII rescues development of small intestinal epithelial cells in Elf3-deficient mice., PMID:17408644
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer., PMID:17127172
A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma., PMID:17034367
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake., PMID:16000578
Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody., PMID:11337573
Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts., PMID:10897044
For research use only. Not for human or drug use.
